Operating Segments

12 Months Ended

Dec. 31, 2024

NOTE 23:-

OPERATING SEGMENTS

The Company applies the principles of IFRS 8, “Operating Segments” (“IFRS 8”), regarding operating segments. The segment reporting is based on internal management reports of the Company’s management, which are regularly reviewed by the Chief Operating Decision Maker (“CODM”) to make decisions about resources to be allocated and assess performance. According to the principles of IFRS 8, the Company’s management determined that it has two reportable segments – (1) development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the Company’s operation); and (2) online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

Segment performance (segment income (loss)) is evaluated based on operating income (loss) in the financial statements. The segment results reported to the CODM include items that are allocated directly to the segments and items that can be allocated on a reasonable basis.

The review of the CODM is carried out according to the results of the segment’s performance. His review does not include certain expenses that are not related specifically to the activity of each of the segments. Those expenses are presented as reconciliation between segments operating results to total operating results in financial statements.

The Group’s CODM is the CEO of the Company.

	Year ended December 31, 2024
	Drug Development		Online Sales		Total
Revenues
External	$	-	$	1,306	$	1,306
Total		-		1,306		1,306

Segment loss (gain)		4,873		2,443		7,316

Equity losses from the investment in MitoCareX						429
Finance expense (income), net						(259	)
Tax income						(14	)

Loss						7,472

	Year ended December 31, 2023
	Drug Development		Online Sales		Total
Revenues
External	$	-	$	2,879	$	2,879
Total		-		2,879		2,879

Segment loss (gain)		5,359		1,456		6,815

Company’s share of losses of company accounted for at equity, net						210
Finance expense (income), net						(1,164	)
Tax expense						22

Loss						5,883

Drug Development Segment

In the year ended December 31, 2024, the Company recognized other income in the amount of $1,288 as a result of a sale of an intangible asset.

Online Sales Segment

In the years ended December 31, 2023, and 2024, the Brand recorded significant losses. As of December 31, 2024, the Company has determined there are signs of decline in the value of the Brand and recognized a loss as a result of impairment to its intangible asset of $1,344 (as of December 31, 2023 - $1,042).

	Year ended December 31, 2022
	Drug Development		Online Sales			Total
Revenues
External	$	-	$	1,347		$	1,347
Total		-		1,347			1,347

Segment loss		8,405		(118	)		8,287
Company’s share of losses of company accounted for at equity, net							109
Finance expense (income), net							(5,818	)
Tax expense							14

Loss							2,592

	As of December 31, 2024
	Drug Development		Online Sales		Total

Segment Assets	$	8,407	$	1,764	$	10,171
Segment Liabilities	$	1,194	$	226	$	1,420

	As of December 31, 2023
	Drug Development		Online Sales		Total

Segment Assets	$	7,069	$	4,113	$	11,182
Segment Liabilities	$	1,441	$	154	$	1,595